epiroprim has been researched along with trimetrexate in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Queener, SF | 1 |
| Gangjee, A; Kisliuk, RL; Queener, SF; Vasudevan, A | 1 |
| Griffin, RJ; Grunwaldt, JD; Lambert, PA; Meek, MA; Queener, SF; Robson, C; Schmidt, D | 1 |
| Cody, V; Galitsky, N; Gangjee, A; Guo, X; Luft, JR; Pangborn, W; Queener, SF | 1 |
| Chan, DC; Fu, H; Queener, SF; Rosowsky, A | 1 |
1 review(s) available for epiroprim and trimetrexate
| Article | Year |
|---|---|
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infections; Pneumonia, Pneumocystis; Structure-Activity Relationship | 1995 |
4 other study(ies) available for epiroprim and trimetrexate
| Article | Year |
|---|---|
2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Liver; Mice; Molecular Structure; Neoplasms, Experimental; Pneumocystis; Pyrimidines; Rats; Recombinant Proteins; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1996 |
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Survival; Folic Acid Antagonists; Indicators and Reagents; Kinetics; Liver; Lymphoma, Large B-Cell, Diffuse; Mice; Pneumocystis; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1997 |
Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Drug Design; Folic Acid Antagonists; Liver; Models, Molecular; NAD; Naphthalenes; Phenylalanine; Pneumocystis; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1998 |
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
Topics: Animals; Azepines; Benzazepines; Folic Acid Antagonists; Models, Molecular; Mycobacterium avium; Pneumocystis carinii; Pteridines; Rats; Solubility; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Water | 2004 |